In 2021, medicated cosmetics accounted for the largest amount of quasi-drugs production in Japan with close to 586.3 billion Japanese yen. Hair remedies accounted for the second largest production value with approximately 228.5 billion yen.
Production value of quasi-drugs in Japan in 2021, by therapeutic category (in billion Japanese yen)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$189 USD $149 USD / Month *
in the first 12 months
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Quasi drugs production value in Japan 2012-2021
- Premium Statistic Medicated cosmetics production quantity in Japan 2016, by item
- Premium Statistic Breakdown of quasi-drugs production in Japan 2021, by therapeutic category
- Premium Statistic Hair remedies production quantity in Japan 2016, by item
- Premium Statistic Median length of orphan and non-orphan drugs in phase III trial 2015
- Premium Statistic Value added of the pharmaceutical industry in Italy 2000-2022
- Premium Statistic Pharmaceutical industry: top EU import partners 2010-2022
- Premium Statistic Biopharmaceuticals market value in Latin America 2022-2027
- Premium Statistic Antibodies market value in Latin America 2022-2027
- Premium Statistic Return on sales in the pharmaceutical industry in Poland 2018-2022
About the region
10
- Premium Statistic Hair remedies production amount in Japan 2021, by item
- Premium Statistic Number of prescription drugs approved by PMDA Japan FY 2015-2021, by type
- Premium Statistic Number of BTC and OTC drugs approved by PMDA Japan FY 2012-2021
- Premium Statistic Number of in vitro diagnostics approved by PMDA Japan FY 2012-2021
- Premium Statistic Number of quasi-drugs approved by PMDA Japan FY 2012-2021
- Premium Statistic Meiji's pharmaceutical business net sales FY 2012-2021
- Premium Statistic Biosimilar market size Japan 2018-2030
- Premium Statistic Number of NME approved Japan 2013-2022
- Premium Statistic R&D expenditure of leading pharmaceutical manufacturers Japan 2020
- Premium Statistic Number of biological drugs approved Japan 2012-2021
Selected statistics
2
Other regions
10
- Basic Statistic Pharmacy revenue share in Sweden 2022, by type of product
- Premium Statistic Massachusetts' medical cannabis spending 2018-2024
- Basic Statistic Leading orphan drugs in development based on net present value 2023
- Premium Statistic Leading orphan designations in the EU by indication 2015
- Premium Statistic Number of cumulative orphan designations accepted in the U.S. 2003-2018
- Basic Statistic Alaska's medical cannabis spending 2018-2024
- Basic Statistic Washington D.C.'s medical cannabis spending 2018-2024
- Basic Statistic Vermont's medical cannabis sales value U.S. 2018-2024
- Basic Statistic Oregon's medical cannabis sales value U.S. 2018-2024
- Basic Statistic Nevada's medical cannabis spending 2018-2024
Related statistics
10
- Premium Statistic Number of biosimilars approved by PMDA Japan 2010-2019
- Premium Statistic Pharmaceutical market size Japan 2008-2015
- Premium Statistic Biopharmaceutical market size forecast Japan 2011-2020
- Premium Statistic Designated quasi drugs market shipment value in Japan 2010-2019
- Premium Statistic OTC drugs market shipment value in Japan 2010-2019
- Premium Statistic Astellas Pharma's net profit FY 2013-2022
- Premium Statistic Sales of medical device and pharmaceutical goods Japan FY 2021, by type
- Premium Statistic Overseas sales of medical device and pharmaceutical goods Japan FY 2021, by type
- Premium Statistic Domestic sales of national medical device and pharma goods Japan FY 2021, by type
- Premium Statistic Number of women receiving free osteoporosis examinations Japan FY 2021, by condition
Further Content: You might find this interesting as well
Statistics
MHLW (Japan). (December 23, 2022). Production value of quasi-drugs in Japan in 2021, by therapeutic category (in billion Japanese yen) [Graph]. In Statista. Retrieved September 27, 2023, from https://www.statista.com/statistics/821009/japan-quasi-drug-production-value-by-therapeutic-category/
MHLW (Japan). "Production value of quasi-drugs in Japan in 2021, by therapeutic category (in billion Japanese yen)." Chart. December 23, 2022. Statista. Accessed September 27, 2023. https://www.statista.com/statistics/821009/japan-quasi-drug-production-value-by-therapeutic-category/
MHLW (Japan). (2022). Production value of quasi-drugs in Japan in 2021, by therapeutic category (in billion Japanese yen). Statista. Statista Inc.. Accessed: September 27, 2023. https://www.statista.com/statistics/821009/japan-quasi-drug-production-value-by-therapeutic-category/
MHLW (Japan). "Production Value of Quasi-drugs in Japan in 2021, by Therapeutic Category (in Billion Japanese Yen)." Statista, Statista Inc., 23 Dec 2022, https://www.statista.com/statistics/821009/japan-quasi-drug-production-value-by-therapeutic-category/
MHLW (Japan), Production value of quasi-drugs in Japan in 2021, by therapeutic category (in billion Japanese yen) Statista, https://www.statista.com/statistics/821009/japan-quasi-drug-production-value-by-therapeutic-category/ (last visited September 27, 2023)
Production value of quasi-drugs in Japan in 2021, by therapeutic category (in billion Japanese yen) [Graph], MHLW (Japan), December 23, 2022. [Online]. Available: https://www.statista.com/statistics/821009/japan-quasi-drug-production-value-by-therapeutic-category/